Loading stock data…
PSTV
$5.50-0.03 (-0.54%)
After Hours$5.45-0.05 (-0.91%)· Last close Jun 9
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Plus Therapeutics, Inc. in the Healthcare sector is trading at $5.50 with a market capitalization of $38M. Wall Street consensus targets $36.00 (4 analysts), implying a +554.5% move over the next 12 months. The stock is currently near its 52-week low of $2.90, remaining 45.8% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +554.5% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$5.50
Potential Upside
3820%
Whystock Fair Value$215.60
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus4 analysts
Mean target$36.00+554.5%
Range$12.00 – $57.00
Fundamentals
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company's lead radiotherapeutic candidate is rhenium obisbemeda, a patented r...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$37.86M
P/E Ratio
Value territory. Trading at a high yield relative to earnings.
0.26
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.37
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-99.75%
Volume
Today's trading volume
106,524
Recent News
Plus Therapeutics gains CAP accreditation for CNSide CSF assay platform
Plus Therapeutics Inc (NASDAQ:PSTV) said its CNSide Diagnostics unit has received accreditation from the College of American Pathologists, a widely recognized standard in laboratory quality, sending shares of the Nasdaq-listed company up 8.7% to $5.89 Thursday. CNSide Diagnostics'...
Plus Therapeutics (PSTV) Reports Q1 Loss, Tops Revenue Estimates
Plus (PSTV) delivered earnings and revenue surprises of -11.11% and +8.21%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Forget the 242% Biotech Meme. This Brain Cancer Stock Has a $38 Analyst Target and Trades at $6
CNS Pharmaceuticals (NASDAQ:CNSP) is back on every biotech watchlist after a 242.36% one-week ramp tied to its Berubicin glioblastoma story. But here’s what you should actually be watching. Holders captured the move; new entrants face tougher math from here. The market cap sits at roughly $6.36 million, the company reported a Q1 2024 net loss ... Forget the 242% Biotech Meme. This Brain Cancer Stock Has a $38 Analyst Target and Trades at $6
Catalyst Pharmaceutical (CPRX) Surpasses Q1 Earnings and Revenue Estimates
Catalyst (CPRX) delivered earnings and revenue surprises of +23.44% and +1.57%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
OmniAb, Inc. (OABI) Reports Q1 Loss, Tops Revenue Estimates
OmniAb, Inc. (OABI) delivered earnings and revenue surprises of +40.00% and +164.13%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?